Table 2.
Characteristics of the included studies of the meta-analysis
| Author | Year | MiRNA | Case | Anatomic location | Assay Method | Country | Gender | Stage | Metastasis | Age | Outcomes | miRNA dysregulation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shuang et al. [13] | 2017 | miR-195 | 122 |
Glottis 61 Supraglottis 42 Subglottis 19 |
qRT-PCR | China | Male (65.5%) |
TI + T2 30 T3 + T4 92 |
N0 81 N + 41 |
53–69 y | OS | Down regulated |
| Zhao et al. [14] | 2018 | miR-145 | 132 |
Glottic 76 Supraglottic 56 |
qRT-PCR | China | Male (86.3%) |
T2 51 T3 + T4 81 |
N0 61 N+ 71 |
48–84 y | OS | Down regulated |
| Gao et al. [15] | 2019 | miR-145-5p | 188 |
Glottic 101 Supraglottic 83 Subglottic 4 |
TCGA | China | Male (88.8%) |
T1 + T2 111 T3 + T4 77 |
N0 142 N+ 46 |
≤ 60y 99 > 60y 89 |
OS | Down regulated |
| Li et al. [16] | 2015 | miR-101 | 80 | Larynx | qRT-PCR | China | Male (70%) |
T1 + T2 40 T3 + T4 40 |
N0 45 N + 35 |
≤ 60y 48 > 60y 32 |
OS | Down regulated |
| de Jong et al. [17] | 2015 | miR-203 | 34 | NA | qRT-PCR | The Netherlands | NA | NA | NA | NA | OS | Down regulated |
| Ding and Qi [18] | 2019 | miR-195 | 182 |
Supraglottic 50 Glottic 95 Subglottic 37 |
qRT-PCR | China | Male (65.3%) | NA |
N0 110 N+ 72 |
NA | OS | Down regulated |
| Fang et al. [19] | 2019 | miR-29c-3p | 66 |
Supraglottic 19 Glottic 45 Subglottic 2 |
qRT-PCR | China | Male (93.9%) |
T1 + T2 21 T3 + T4 45 |
N0 36 N+ 30 |
≤ 60y 26 > 60y 40 |
OS | Down regulated |
| He et al. [20] | 2017 | miR-300 | 133 | Larynx | qRT-PCR | China | Male (65.4%) |
T1 + T2 67 T3 + T4 66 |
N0 73 N+ 60 |
≤ 50y 47 > 50y 86 |
OS | Down regulated |
| Hui et al. [21] | 2019 |
miR-10a miR-16–2 |
22 | Larynx | TCGA | China | NA | NA | NA | NA | OS, RFS | Down regulated |
| Re et al. [22] | 2015 | miR-34c-5p | 90 |
Supraglottic 19 Transglottic 66 Subglottic 5 |
qRT-PCR | Italy | Male (96.6%) |
T3 60 T4 30 |
N0 29 N+ 61 |
Mean 66.51 | OS | Down regulated |
| Xu et al. [23] | 2016 | miR-149 | 97 | Larynx | qRT-PCR | China | NA |
T1 + T2 59 T3 + T4 38 |
N0 69 N+ 28 |
≤ 60y 46 > 60y 51 |
OS | Down regulated |
| Tian et al. [24] | 2014 | miR-203 | 56 |
Glottic 30 Supraglottic 26 |
qRT-PCR | China | Male (71.43%) |
T1 + T2 24 T3 + T4 32 |
N0 23 N+ 23 |
≤ 59y 32 > 59y 24 |
OS | Down regulated |
| Hess et al. [25] | 2017 |
miR-155 miR-146a miR-200b |
149 |
Oropharynx 77 Hypopharynx 72 |
qRT-PCR | Germany | NA | NA | NA | NA | OS, RFS | Down regulated |
| Zhao et al. [26] | 2018 | miR-181a | 127 |
Supraglottic 50 Glottic 77 |
qRT-PCR | China | Male (88.6%) |
T1 + T2 53 T3 + T4 74 |
N0 65 N+ 62 |
≤ 60y 79 > 60y 48 |
OS | Down regulated |
| Zhao et al. [27] | 2018 | miR-196b | 113 |
Supraglottic 43 Glottic 70 |
qRT-PCR | China | Male (85%) |
T1 + T2 47 T3 + T4 66 |
N0 65 N+ 48 |
≤ 60y 71 > 60y 42 |
OS | Upregulated |
| Zhao et al. [28] | 2018 | miR-155 | 120 |
Supraglottic 46 Glottic 74 |
qRT-PCR | China | Male (89.2%) |
T1 + T2 67 T3 + T4 53 |
N0 88 N+ 32 |
≤ 60y 63 > 60y 57 | OS | Upregulated |
| Guan et al. [29] | 2016 | miR-675 | 62 |
Larynx 46 Hypopharynx 14 Oropharynx 2 |
qRT-PCR | China | Male (94%) | NA | NA | Mean 64 | OS | Upregulated |
| Arantes et al. [30] | 2017 |
miR-21 miR-494 miR-720 |
71 |
Oropharynx 35 Larynx 28 Hypopharynx 8 |
TCGA | Brazil | Male (95.8%) |
T1 + T2 46 T3 + T4 25 |
N0 35 N+ 36 |
NA | OS | Upregulated |
| Avissar et al. [31] | 2009 | miR-21 | 169 | Larynx | qRT-PCR | USA | Male (68%) |
T1 + T2 46 T3 + T4 118 |
NA | Mean 61.5 | OS | Upregulated |
| Langevin et al. [32] | 2011 | miR-137 | 67 | Larynx | qRT-PCR | USA | Male (74.6%) |
T1 + T2 35 T3 + T4 32 |
N0 31 N+ 36 |
Mean 62.4 | OS | Upregulated |
| Qiang et al. [33] | 2019 | miR-31 | 55 | Larynx | qRT-PCR | China | Male (57.1%) |
T1 + T2 21 T3 + T4 35 |
NA | Mean 63.2 | OS | Upregulated |
| Wu et al. [34] | 2014 | miR-9 | 103 |
Supraglottic 66 Glottic 37 |
qRT-PCR | China | Male (47.5%) |
T1 + T2 55 T3 + T4 48 |
N0 31 N+ 74 |
≤ 60y 41 > 60y 62 |
OS | Upregulated |
| Wu et al. [35] | 2014 | miR-19a | 83 |
Supraglottic 35 Glottic 48 |
qRT-PCR | China | Male (68.6%) |
T1 + T2 52 T3 + T4 31 |
N0 54 N + 29 |
≤ 56y 42 > 56y 41 |
OS | Upregulated |
| Zhang et al. [36] | 2015 | miR-23a | 52 | Larynx | qRT-PCR | China | Male (86.5%) |
T1 + T2 24 T3 + T4 28 |
N0 34 N + 18 |
≤ 60y 22 > 60y 30 |
OS | Upregulated |
| Hu et al. [37] | 2014 | miR-21 | 46 |
Glottic 33 Supraglottic 11 Subglottic 2 |
qRT-PCR | China | Male (91.3%) |
T0 + T1 + T2 21 T3 + T4 25 |
NA | Mean 59.2 | OS | Upregulated |
| Saito et al. [38] | 2013 | miR-196a | 84 | Larynx | qRT-PCR | Japan | NA | NA | NA | NA | OS | Upregulated |
| Re and Magliulo [39] | 2017 | miR-34c-5p | 43 |
Supraglottic 8 Transglottic 33 Subglottic 2 |
qRT-PCR | Italy | Male (97.67%) |
T3 31 T4 12 |
N0 27 N+ 16 |
Mean 66.51 | DFS | Downregulated |
| Shen et al. [40] | 2012 | miR-34a | 69 | Larynx | qRT-PCR | China | NA |
T1 + T2 42 T3 + T4 27 |
N0 24 N+ 45 |
≤ 60y 33 > 60y 36 |
DFS | Downregulated |
| Danielle Maia [41] | 2015 | mIR-296-5P | 34 |
Supraglottic 7 Glottic 27 |
TCGA | Brazil | Male (88.2%) |
TI 16 T2 18 |
NA |
≤ 60y 16 > 60y 18 |
DFS | Downregulated |
| Ogawa et al. [42] | 2012 | miR-34a | 24 | Larynx | TCGA | Japan | Male (66.6%) |
T3 10 T4 14 |
NA |
≤ 60y 10 > 60y 14 |
DFS | Downregulated |
| Pantazis et al. [43] | 2020 | miR-20b-5p | 105 | Larynx | qRT-PCR | Athens | Male (63.1%) |
T1 + T2 31 T3 + T4 74 |
NA | NA | DFS | Downregulated |
| Wilkins [44] | 2019 | miR-100 | 136 | Larynx | TCGA | USA | NA | NA | NA | NA | DFS | Downregulated |
| Li et al. [45] | 2019 | miR-424-5p | 106 |
Glottic 55 Supraglottic 40 Subglottic 3 Transglottic 8 |
TCGA | China | Male (93.3%) |
T1 + T2 58 T3 + T4 48 |
N0 80 N+ 26 |
≤ 60y 47 > 60y 59 |
DFS | Upregulated |
| Childs et al. [46] | 2009 | miR-let-7d | 73 |
Oropharynx 32 Hypopharynx 9 Larynx 32 |
qRT-PCR | USA | Male (68%) |
T1 + T2 17 T3 + T4 56 |
NA |
≤ 60y 30 > 60y 43 |
OS | Downregulated |
| Liu et al. [47] | 2017 | miR-let-7a | 131 | Larynx | qRT-PCR | China | Male (33%) | T1 + T2 51 T3 + T4 80 | NA |
≤ 60y 88 > 60y 43 |
OS | Downregulated |
| Wilkins et al. [48] | 2018 | miR-let-7a | 2083 |
Pharynx 1458 Larynx 625 |
TCGA | USA | Male (24.5%) |
T1 + T2 541 T3 + T4 1542 |
NA | NA | OS | Downregulated |